The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice

The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice

Introduction. CDK4/6 inhibitors in combination with endocrine therapy (ET) are the current standard of care for patients with HR+ HER2- advanced and metastatic breast cancer (eBC and mBC). Evidence of the clinical efficacy of CDK4/6 inhibitors has been obtained in several randomized clinical trials...

Full description

Saved in:
Bibliographic Details
Main Authors: I. E. Khatkov, I. I. Andreyashkina, I. D. Trotsenko, O. N. Matveeva, V. A. Reznikov
Format: Article
Language:Russian
Published: Publishing House OKI 2025-07-01
Series:Реальная клиническая практика: данные и доказательства
Subjects:
cdk4/6 inhibitors
ribociclib
palbociclib
abemaciclib
real-life clinical practice
locally advanced breast cancer
metastatic breast cancer
Online Access:https://www.myrwd.ru/jour/article/view/105
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items